title: Field effect of two commercial preparations of botulinum toxin type A: a prospective, double-blind, randomized clinical trial.
abstract: BACKGROUND
  The dose equivalence of commonly used commercial preparations of botulinum toxin type A, Dysport (abotulinumtoxinA [ABO] 500 U, Ipsen Biopharm Limited, Wrexham, United Kingdom) and Botox (onabotulinumtoxinA [ONA] 100 U, Allergan, Irvine, CA), remains unclear.
  
  
  OBJECTIVE
  We sought to evaluate the field effect for ABO and ONA at dose equivalences of 2.5:1.0 U and 2.0:1.0 U, in both muscular and sweat gland activity.
  
  
  METHODS
  In all, 59 female patients with forehead wrinkles were enrolled. Patients were randomized for dose equivalence between ABO and ONA, group A (2.0:1.0 U, ABO:ONA) or group B (2.5:1.0 U, ABO:ONA) administered in the frontalis muscles. Clinical assessment, Minor test, and electromyography evaluations were performed at baseline, 28 days, and 112 days.
  
  
  RESULTS
  In group B, the field of anhidrotic effect of ABO showed a greater area and larger horizontal diameter than ONA at 28 and 112 days. At maximum frontalis muscle activity (day 112) patients receiving ABO demonstrated greater improvement based on the Wrinkle Severity Scale. No differences were found in frontalis muscle activity at rest between groups A and B based on results of Wrinkle Severity Scale, electromyography, and interindividual variability data at 28 and 112 days.
  
  
  CONCLUSIONS
  Currently, there are no objective measurements other than electromyography to evaluate the field effect of botulinum toxin type A in muscles.
  
  
  CONCLUSIONS
  At a dose equivalence of 2.0:1.0 U (ABO:ONA), similar field effects were found for both muscle and sweat gland activity. At a higher dose equivalence of 2.5:1.0 U (ABO:ONA), injections of ABO showed greater area and larger horizontal diameter in field of anhidrotic effect at 28 and 112 days than ONA.
authors: Brazilian Center for Studies in Dermatology, Porto Alegre, Brazil. doris@hexsel.com.br
authors: Doris
authors: D
authors: Hexsel
authors: Cristiano
authors: C
authors: Brum
authors: Débora Zechmeister
authors: DZ
authors: do Prado
authors: Mariana
authors: M
authors: Soirefmann
authors: Francisco Telechea
authors: FT
authors: Rotta
authors: Taciana
authors: T
authors: Dal'Forno
authors: Ticiana C
authors: TC
authors: Rodrigues
mesh_terms: D000200:Action Potentials; D000293:Adolescent; D000328:Adult; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005152:Facial Muscles / Q000187:drug effects / Q000294:innervation; D005260:Female; D005546:Forehead; D006801:Humans; D008875:Middle Aged; D009498:Neurotoxins / Q000008:administration & dosage*; D011446:Prospective Studies; D012720:Severity of Illness Index; D015595:Skin Aging / Q000187:drug effects* / Q000473:pathology*; D013545:Sweat Glands / Q000187:drug effects; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D009498:Neurotoxins; D019274:Botulinum Toxins, Type A